Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P62988 (
Ubiquitin
)
4,326
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To attenuate injury during cholestasis, adaptive changes in bile acid transporter expression in the liver provide alternative bile acid excretory pathways.
Apical sodium-dependent bile acid transporter
(
ASBT
) (SLC10A2), only expressed in the liver on the cholangiocyte apical membrane, is rapidly regulated in response to inflammation and bile acids. Here, we studied the mechanisms controlling
ASBT
protein levels in cholangiocytes to determine whether
ASBT
expression is regulated by ubiquitination and disposal through the proteasome. Protein turnover assays demonstrated that
ASBT
is an unstable and short-lived protein. Treatment with MG-132, a proteasome inhibitor, causes time-dependent increased
ASBT
levels and increased intracellular accumulation of
ASBT
. In cells cotransfected with green fluorescent protein-tagged
ASBT
and hemagglutinin-tagged ubiquitin, we demonstrated coimmunoprecipitation and colocalization of
ASBT
and ubiquitin. Interleukin-1beta (IL-1beta) induced down-regulation of
ASBT
is abrogated by a JNK inhibitor and is accompanied by an increase in
ASBT
polyubiquitin
conjugates and a reduced
ASBT
half-life. In phosphorylation-deficient S335A and T339A mutants, the
ASBT
half-life is markedly prolonged, IL-1beta-induced
ASBT
ubiquitination is significantly reduced, and IL-1beta fails to increase
ASBT
turnover. These results indicate that
ASBT
undergoes ubiquitin-proteasome degradation under basal conditions and that
ASBT
proteasome disposal is increased by IL-1beta due to JNK-regulated serine/threonine phosphorylation of
ASBT
protein at both Ser-335 and Thr-339. These studies are the first report of regulation of a bile acid transporter expression by the ubiquitin-proteasome pathway.
...
PMID:Degradation of the apical sodium-dependent bile acid transporter by the ubiquitin-proteasome pathway in cholangiocytes. 1530 98